Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Liabilities and Shareholders Equity (2018 - 2023)

Avai Bio's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $291246.0 for Q4 2023.

  • For Q4 2023, Liabilities and Shareholders Equity rose 2.23% year-over-year to $291246.0; the TTM value through Mar 2024 reached $830726.0, down 33.74%, while the annual FY2023 figure was $241460.0, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2023 was $291246.0 at Avai Bio, up from $265061.0 in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $816269.0 in Q3 2020 and bottomed at -$122491.0 in Q3 2019.
  • The 4-year median for Liabilities and Shareholders Equity is $284890.0 (2022), against an average of $296881.3.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 291.41% in 2019 before it skyrocketed 3764.43% in 2020.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $166259.0 in 2019, then surged by 281.47% to $634232.0 in 2020, then plummeted by 55.08% to $284890.0 in 2022, then increased by 2.23% to $291246.0 in 2023.
  • Per Business Quant, the three most recent readings for AVAI's Liabilities and Shareholders Equity are $291246.0 (Q4 2023), $265061.0 (Q3 2023), and $274419.0 (Q2 2023).